ClinicalTrials.gg
CompletedNCT05243316Updated May 31, 2023

Risk of Pneumothorax With and Without Chest Tube Clamping in Patients With Pleural Pathology

An interventional study of Clamping and Non Clampling in Pneumothorax, Chest Tube and Pleural Diseases, sponsored by National Institute of Respiratory Diseases, Mexico. Completed at 1 site in Mexico. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by National Institute of Respiratory Diseases, Mexico · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Through this randomized controlled clinical trial, we aim to identify whether there is a difference in the incidence of 24 hour pneumothorax after chest tube removal, in two blindly randomized groups of patients: The first group with chest tube clamping 6 hours prior to removal, and the second group there will be no chest tube clamping.

The data will be prospectively collected from patient records from the National Institute of Respiratory Diseases Ismael Cosío Villegas.

Read the detailed description

Patients with an indication of chest tube removal will be randomized to two possible arms: clamping (for 6 hours before removal) or not clamping (immediate removal).

Incidence of 24hour pneumothorax after chest tube removal will be recorded.

02

Conditions studied

  • Pneumothorax
  • Chest Tube
  • Pleural Diseases

Keywords

  • Chest tube
  • Pneumothorax
  • Pleural Diseases
03

In context

Pneumothorax

183 studies on the registry are indexed under Pneumothorax; 41 are open to participants now.

This study's enrollment of 93 is close to the median of 100 across 111 interventional studies indexed under Pneumothorax.

Browse Pneumothorax studies →

Lead sponsor

National Institute of Respiratory Diseases, Mexico is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 16 years and more.
  • Patients hospitalized in the National Institute of Respiratory Diseases.
  • Patients who had a chest tube placement during their stay at the hospital, by any cause.

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to sign the and who refuse to participate in the study.
  • Patients who die before randomization.
  • Patients who gets chest tube removal before being randomized.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Active comparator
    Patients with clamping of the chest tube

    Patients with 6hour clamping prior to removal

    Procedure: Clamping

  • Sham comparator
    Patients without clamping of the chest tube

    Patients will have chest tube removed immediately

    Procedure: Non Clampling

Interventions

  • ProcedureClamping

    There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.

  • ProcedureNon Clampling

    There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.

06

What researchers measure

Primary outcomes

  1. Incidence of pneumothorax after chest tube removal with chest tube clamping

    Cases of pneumothorax after chest tube removal despite clamping

    Time frame: After 24 hours of procedure

  2. Incidence of pneumothorax after chest tube removal without chest tube clamping

    Cases of pneumothorax after chest tube removal despite clamping

    Time frame: After 24 hours of procedure

Secondary outcomes

  1. Hospital days of stay

    Hospital days of stay

    Time frame: Through study completion, an average of 1 month

07

Study locations

1 site
  • National Institute of Respiratory Diseases
    Mexico City, 14080, Mexico
08

References and documents

Individual participant data

Plan to share: Yes — Database will be available once the protocol is complete

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Once completed for one year

Access criteria: Free access

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Mar 2023, 15 months.

Of 41 non-industry interventional studies with no phase under Pneumothorax, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 34. This study's 15 months is below that.

Counting every sponsor, half of 43 studies reached it within 26 months; a quarter within 14 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Feb 17, 2022
StartActual
Dec 22, 2021
Primary completionActual
Mar 31, 2023
CompletionActual
Apr 15, 2023
Last update
May 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05243316
Lead sponsor
National Institute of Respiratory Diseases, Mexico
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Dec 22, 2021
Primary completion
Mar 31, 2023
Completion
Apr 15, 2023
Last update
May 31, 2023

Study contacts

Sebastian Rodriguez, Doctor
study director · National Institute of Respiratory Diseases

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion